Global patent index - EP 0969842 A1

EP 0969842 A1 2000-01-12 - PHARMACEUTICAL COMPOSITION

Title (en)

PHARMACEUTICAL COMPOSITION

Title (de)

PHARMAZEUTISCHE ZUSAMMENSETZUNG

Title (fr)

COMPOSITION PHARMACEUTIQUE

Publication

EP 0969842 A1 (EN)

Application

EP 98912622 A

Priority

  • GB 9800885 W
  • GB 9706089 A

Abstract (en)

[origin: WO9842344A1] This invention relates to a pharmaceutical composition for oral administration comprising a carrier and, as an active ingredient, a 5-HT1 agonist, characterised in that the composition is formulated to reduce pre-systemic metabolism of said 5-HT1 agonist. A process for preparing such a composition and the use of such a composition for the treatment of anxiety, depression, attention deficit disorder and/or panic disorders and/or as a memory enhancer are also provided.

IPC 1-7 (main, further and additional classification)

A61K 31/505; A61K 9/00; A61K 31/435; A61K 31/445; A61K 31/495

IPC 8 full level (invention and additional information)

A61K 9/20 (2006.01); A61K 9/00 (2006.01); A61K 31/4045 (2006.01); A61K 31/438 (2006.01); A61K 31/45 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/535 (2006.01); A61K 45/00 (2006.01); A61P 25/00 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01); A61P 25/28 (2006.01); A61P 25/30 (2006.01); A61P 37/02 (2006.01); A61P 43/00 (2006.01)

CPC (invention and additional information)

A61K 9/0056 (2013.01); A61K 31/438 (2013.01); A61K 31/45 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01)

Citation (examination)

  • EP 0486666 A1
  • SUNADA ET AL: "Preparation and Evaluation of a Compressed Tablet Rapidly Disintegrating in the Oral Cavity" CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 44, no. 11, 1996, pages 2121-2127,
  • "the national formulary" THE UNITED STATES PHARMACOPEIA, vol. 1, 2007,
  • See also references of WO 9842344A1

Citation (third parties)

Third party :

  • EP 0486666 B1
  • YUNXIA BI; ET AL: 'PREPARATION AND EVALUATION OF A COMPRESSED TABLET RAPIDLY DISINTEGRATING IN THE ORAL CAVITY' CHEM. PHARM. BULL. vol. 44, no. 11, 1996, pages 2121 - 2127, XP000636227
  • UNITED STATES PHARMACOPEIAL CONVENTION: 'THE UNITED STATES PHARMACOPEIA. THE NATIONAL FORMULARY', 2006, UNITED STATES PHARMACOPEIAL CONVENTION, US, ISBN 1-889788-47-3 page 629, XP003019579
  • DOENICKE A. ET AL.: 'Effective improvement of symptoms in patients with acute migraine by GR43175 administered in dispersible tablets' CEPHALALGIA vol. 9, no. SUPPL.9, 1989, pages 89 - 92, XP008094994
  • C.J. THOMSON (STUDY COORDINATOR): 'A study to compare oral sumatriptan with oral aspirin plus Oral Metoclopramide in the Acute Treatment of Migraine' EUR NEUROL vol. 32, no. 3, 1992, pages 177 - 184, XP008095009
  • J. P. PATTEN AND THE ORAL SUMATRIPTAN DOSE-DEFINING STUDY GROUP: 'Clinical experience with oral sumatriptan: a placebo-controlled, dose-ranging study' J NEUROL vol. 238, no. SUPPL.1, February 1991, pages 1432 - 1459, XP008094995
  • LACEY L.F. ET AL.: 'Single dose pharmacokinetics of sumatriptan in healthy volunteers' EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY vol. 47, no. 6, February 1995, pages 543 - 548, XP008094998

Designated contracting state (EPC)

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

EPO simple patent family

WO 9842344 A1 19981001; AU 6740298 A 19981020; EP 0969842 A1 20000112; GB 9706089 D0 19970514; JP 2001518925 A 20011016

INPADOC legal status

2009-06-10 [18D] DEEMED TO BE WITHDRAWN

- Effective date: 20081218

2001-07-04 [17Q] FIRST EXAMINATION REPORT

- Effective date: 20010518

2000-07-05 [RAP1] TRANSFER OF RIGHTS OF AN EP APPLICATION

- Owner name: R.P. SCHERER TECHNOLOGIES, INC.

2000-01-12 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 19990902

2000-01-12 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A1

- Designated State(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE